BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossetti GG, Ossorio MA, Rempel S, Kratzel A, Dionellis VS, Barriot S, Tropia L, Gorgulla C, Arthanari H, Thiel V, Mohr P, Gamboni R, Halazonetis TD. Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. Sci Rep 2022;12:2505. [PMID: 35169179 DOI: 10.1038/s41598-022-06306-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Luan XD, Chen BX, Shang WJ, Yin WC, Jin Y, Zhang LK, Xu HE, Zhang SY. Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376. Acta Pharmacol Sin 2023;44:255-7. [PMID: 35773339 DOI: 10.1038/s41401-022-00929-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Parigger L, Krassnigg A, Schopper T, Singh A, Tappler K, Köchl K, Hetmann M, Gruber K, Steinkellner G, Gruber CC. Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs. Front Med (Lausanne) 2022;9:1061142. [PMID: 36590977 DOI: 10.3389/fmed.2022.1061142] [Reference Citation Analysis]
3 Ivanova YO, Voronina AI, Skvortsov VS. [The prediction of SARS-CoV-2 main protease inhibition with filtering by position of ligand]. Biomed Khim 2022;68:444-58. [PMID: 36573412 DOI: 10.18097/PBMC20226806444] [Reference Citation Analysis]
4 Yin S, Mei S, Li Z, Xu Z, Wu Y, Chen X, Liu D, Niu M, Li J. Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1037993] [Reference Citation Analysis]
5 Zaremba A, Zaremba P, Zahorodnia S. De novo designed inhibitor has high affinity to four variants of the RBD of S-glycoprotein of SARS-CoV-2 - an in silico study. Journal of Biomolecular Structure and Dynamics 2022. [DOI: 10.1080/07391102.2022.2141886] [Reference Citation Analysis]
6 Xu Z, Zou Y, Gao X, Niu M, Li J, Xue L, Jiang S. Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. Front Pharmacol 2022;13:1041331. [DOI: 10.3389/fphar.2022.1041331] [Reference Citation Analysis]
7 Parigger L, Krassnigg A, Schopper T, Singh A, Tappler K, Köchl K, Hetmann M, Gruber K, Steinkellner G, Gruber CC. Changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.. [DOI: 10.21203/rs.3.rs-1858067/v2] [Reference Citation Analysis]
8 Gruber C, Parigger L, Krassnigg A, Schopper T, Singh A, Tappler K, Köchl K, Hetmann M, Gruber K, Steinkellner G. Recent changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.. [DOI: 10.21203/rs.3.rs-1858067/v1] [Reference Citation Analysis]
9 Galehban MH, Zeynizadeh B, Mousavi H. Introducing Fe3O4@SiO2@KCC-1@MPTMS@CuII catalytic applications for the green one-pot syntheses of 2-aryl(or heteroaryl)-2,3-dihydroquinazolin-4(1H)-ones and 9-aryl-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-diones. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.134017] [Reference Citation Analysis]
10 Agost-Beltrán L, de la Hoz-Rodríguez S, Bou-Iserte L, Rodríguez S, Fernández-de-la-Pradilla A, González FV. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Molecules 2022;27:2523. [PMID: 35458721 DOI: 10.3390/molecules27082523] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Sepay N, Chakrabarti S, Afzal M, Alarifi A, Mal D. Identification of 4-acrylamido- N -(pyridazin-3-yl)benzamide as anti-COVID-19 compound: a DFTB, molecular docking, and molecular dynamics study. RSC Adv 2022;12:24178-86. [DOI: 10.1039/d2ra04333e] [Reference Citation Analysis]
12 Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zarębska-Michaluk D, Rezaei N, Rzymski P. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep 2022;74:1255-78. [PMID: 35871712 DOI: 10.1007/s43440-022-00388-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]